Recombinant deamidated gliadin antigen
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 16, 2021
Grant Date -
Oct 26, 2017
app pub date -
Jun 8, 2017
filing date -
Dec 5, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Methods of diagnosing celiac disease in a subject are provided. In some embodiments, the method comprises contacting a sample of bodily fluid from the subject with an antigen comprising a recombinant or synthetic deamidated gliadin protein, wherein the deamidated gliadin protein comprises a hexamer of peptides each having the sequence of SEQ ID NO:1; and detecting an antibody from the sample that specifically binds to the antigen, thereby diagnosing celiac disease in the subject.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully